Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurocognitive Disorders
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Alzheimer's Disease and Dementia
Researchers sought to assess the clinical prevalence of Alzheimer disease in patients with leprosy, also known as Hansen’s disease, and inflammasome activity.
Multiple Sclerosis
In a prospective cohort study, researchers assessed whether adverse childhood experiences may increase the risk for multiple sclerosis in women.
Neurobehavioral Disorders
The US Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years, and recommends anxiety screening for children aged 8 to 18 years.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Neurobehavioral Disorders
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
MeetingInsight
The American Academy of Neurology hosted its 74th annual meeting in Seattle, Washington. Michael S. Okun, MD, shares his key takeaways from the plethora of sessions discussing advancements in the management of “off” episodes for patients with Parkinson disease. New drug delivery systems and formulations for carbidopa/levodopa (CD/LD) are among the exciting changes from the 2022 AAN meeting.
HowToTreat
Spinal muscular atrophy is one of the most common causes of infant mortality. Historically, SMA treatment consisted of supportive care only. The arrival of disease-modifying therapies has made a major impact on the prognosis for patients with SMA. This article highlights therapies approved by the FDA, such as survival motor neuron 2 (SMN2) modulators, SMN1 gene therapy, and the use of newborn screening to commence treatment in the pre-symptomatic period.
General Neurology
This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.
